Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential

Abstract This study aimed to determine whether promoter methylation of N-acetyltransferase 2 (NAT2), a metabolic enzyme responsible for drug metabolism and detoxification, was correlated with clinical parameters indicating anti-tuberculosis drug-induced liver injury (ATDILI) in tuberculosis patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiraphun Jittikoon, Wacharapol Saengsiwaritt, Noppadol Chanhom, Usa Chaikledkaew, Sukanya Wattanapokayakit, Surakameth Mahasirimongkol, Wanvisa Udomsinprasert
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-95050-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850208627223166976
author Jiraphun Jittikoon
Wacharapol Saengsiwaritt
Noppadol Chanhom
Usa Chaikledkaew
Sukanya Wattanapokayakit
Surakameth Mahasirimongkol
Wanvisa Udomsinprasert
author_facet Jiraphun Jittikoon
Wacharapol Saengsiwaritt
Noppadol Chanhom
Usa Chaikledkaew
Sukanya Wattanapokayakit
Surakameth Mahasirimongkol
Wanvisa Udomsinprasert
author_sort Jiraphun Jittikoon
collection DOAJ
description Abstract This study aimed to determine whether promoter methylation of N-acetyltransferase 2 (NAT2), a metabolic enzyme responsible for drug metabolism and detoxification, was correlated with clinical parameters indicating anti-tuberculosis drug-induced liver injury (ATDILI) in tuberculosis patients and might emerge as an ATDILI biomarker. NAT2 promoter methylation in blood leukocyte of 102 tuberculosis patients (49 ATDILI cases and 53 non-ATDILI cases) and 100 healthy controls were quantified using quantitative real-time methylation-specific polymerase chain reaction. Compared to healthy volunteers, tuberculosis patients had significantly reduced NAT2 demethylation index. Compared with non-ATDILI patients, NAT2 demethylation index was significantly decreased in ATDILI patients. An independent association was found between lower NAT2 demethylation index and increased susceptibility to ATDILI. NAT2 demethylation index quantified after starting treatment within 1–7 days was negatively correlated with serum aminotransferases measured within 8–60 days of treatment. ROC curve analysis uncovered that NAT2 demethylation index was found to be a more sensitive and specific biomarker for ATDILI when compared to serum aminotransferases measured following treatment initiation within 1–7 days. Kaplan–Meier analysis unveiled a notable association between lower NAT2 demethylation index and a higher incidence of ATDILI in tuberculosis patients, as confirmed by Cox regression analysis while accounting for confounding variables. A reduction in NAT2 demethylation index could reflect ATDILI progression and potentially be used as a new, specific biomarker for ATDILI.
format Article
id doaj-art-4f08fdefc7b54769a19ac3f4af7d712a
institution OA Journals
issn 2045-2322
language English
publishDate 2025-03-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-4f08fdefc7b54769a19ac3f4af7d712a2025-08-20T02:10:12ZengNature PortfolioScientific Reports2045-23222025-03-0115111110.1038/s41598-025-95050-6Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potentialJiraphun Jittikoon0Wacharapol Saengsiwaritt1Noppadol Chanhom2Usa Chaikledkaew3Sukanya Wattanapokayakit4Surakameth Mahasirimongkol5Wanvisa Udomsinprasert6Department of Biochemistry, Faculty of Pharmacy, Mahidol UniversityDepartment of Biochemistry, Faculty of Pharmacy, Mahidol UniversityDepartment of Biochemistry, Faculty of Pharmacy, Mahidol UniversitySocial and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol UniversityDivision of Genomic Medicine and Innovation Support, Department of Medical Sciences, Genomic Medicine Centre, Ministry of Public HealthDivision of Genomic Medicine and Innovation Support, Department of Medical Sciences, Genomic Medicine Centre, Ministry of Public HealthDepartment of Biochemistry, Faculty of Pharmacy, Mahidol UniversityAbstract This study aimed to determine whether promoter methylation of N-acetyltransferase 2 (NAT2), a metabolic enzyme responsible for drug metabolism and detoxification, was correlated with clinical parameters indicating anti-tuberculosis drug-induced liver injury (ATDILI) in tuberculosis patients and might emerge as an ATDILI biomarker. NAT2 promoter methylation in blood leukocyte of 102 tuberculosis patients (49 ATDILI cases and 53 non-ATDILI cases) and 100 healthy controls were quantified using quantitative real-time methylation-specific polymerase chain reaction. Compared to healthy volunteers, tuberculosis patients had significantly reduced NAT2 demethylation index. Compared with non-ATDILI patients, NAT2 demethylation index was significantly decreased in ATDILI patients. An independent association was found between lower NAT2 demethylation index and increased susceptibility to ATDILI. NAT2 demethylation index quantified after starting treatment within 1–7 days was negatively correlated with serum aminotransferases measured within 8–60 days of treatment. ROC curve analysis uncovered that NAT2 demethylation index was found to be a more sensitive and specific biomarker for ATDILI when compared to serum aminotransferases measured following treatment initiation within 1–7 days. Kaplan–Meier analysis unveiled a notable association between lower NAT2 demethylation index and a higher incidence of ATDILI in tuberculosis patients, as confirmed by Cox regression analysis while accounting for confounding variables. A reduction in NAT2 demethylation index could reflect ATDILI progression and potentially be used as a new, specific biomarker for ATDILI.https://doi.org/10.1038/s41598-025-95050-6N-Acetyltransferase 2 (NAT2)Promoter methylationAnti-tuberculosis drug-induced liver injuryTuberculosisBiomarker
spellingShingle Jiraphun Jittikoon
Wacharapol Saengsiwaritt
Noppadol Chanhom
Usa Chaikledkaew
Sukanya Wattanapokayakit
Surakameth Mahasirimongkol
Wanvisa Udomsinprasert
Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
Scientific Reports
N-Acetyltransferase 2 (NAT2)
Promoter methylation
Anti-tuberculosis drug-induced liver injury
Tuberculosis
Biomarker
title Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
title_full Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
title_fullStr Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
title_full_unstemmed Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
title_short Association of NAT2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
title_sort association of nat2 promoter hypermethylation with susceptibility to hepatotoxicity due to antituberculosis drugs and biomarker potential
topic N-Acetyltransferase 2 (NAT2)
Promoter methylation
Anti-tuberculosis drug-induced liver injury
Tuberculosis
Biomarker
url https://doi.org/10.1038/s41598-025-95050-6
work_keys_str_mv AT jiraphunjittikoon associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT wacharapolsaengsiwaritt associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT noppadolchanhom associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT usachaikledkaew associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT sukanyawattanapokayakit associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT surakamethmahasirimongkol associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential
AT wanvisaudomsinprasert associationofnat2promoterhypermethylationwithsusceptibilitytohepatotoxicityduetoantituberculosisdrugsandbiomarkerpotential